 |
- Home
- Clinical Perspectives
- Business Perspectives
- Patient Care
- Learning
- Community
- Products
- Careers
- About Us
E-mail Alerts
RSS Feeds
SITE TOOLS
The program, being implemented under the U.S. Food and Drug Administration (FDA) guidelines covering compassionate use of an investigational new drug, began at St. Luke’s Hospital & Health Network in Bethlehem, Pa. Provectus recently announced that all patients in the phase 2 clinical trial for metastatic melanoma had been treated, according to the press release. The program was initiated in Australia in June 2009. Both the U.S. program and the Australian program make PV-10 available only for cancer indications that do not involve visceral organs. Available indications include certain breast cancers, basal cell carcinoma, squamous cell carcinoma, certain head and neck cancers and melanoma. Provectus plans to expand the compassionate use program to other U.S. sites in the coming months. |   Practice Tools Coding Counselor Simple and accurate ICD-9 code search. Start Here  Formulary Counselor Find health plan drug coverage in your area. Start Here  Patient Education Print customized patient education handouts. Start Here  Surgical Video Center On-demand surgery demos and presentations. Start Here    
|
